A preliminary study of manipulation under anaesthesia for secondary frozen shoulder following breast cancer treatment

Introduction The aim of this paper is to present the results of manipulation under anaesthesia (MUA) and injection of local anaesthetic and corticosteroid followed by a physiotherapy regime for secondary frozen shoulder after breast cancer treatment (surgery, radiotherapy), and to compare them with a control group. Methods Patients referred to the senior author for secondary frozen shoulder following breast cancer treatment over a ten-year period were investigated. Recorded data included age, treatment for breast cancer, length of symptoms, Oxford shoulder score (OSS) and range of motion before and after shoulder MUA. These data were compared with a control group of patients with frozen shoulder. Results A total of 263 patients were referred with 281 frozen shoulders. Of these, 7 patients (7 shoulders) had undergone previous breast cancer treatment and the remaining 256 patients (274 shoulders) formed the control group. None of the patients were diabetic. The mean preoperative OSS was 31 for the study group and 27 for the control group, improving to 43 for both groups following MUA. Forty-two per cent of the study group and fifteen per cent of the control group had a second MUA subsequently. At the long-term follow-up appointment, 71% of the study group patients were satisfied with their result. Conclusions The results of this preliminary study suggest that MUA, corticosteroid injection and subsequent physiotherapy have achieved good final results in a series of patients with frozen shoulder secondary to breast cancer treatment. Members of the multidisciplinary team looking after breast cancer patients should be aware of this management option and, on manifestation of this pathology, should refer the patient to an orthopaedic surgeon.

Download Full-text

The effects of complete decongestive therapy on the extent of secondary lymphoedema in women after breast cancer treatment

Physiotherapy ◽

10.1515/physio-2015-0001 ◽

2015 ◽

Vol 23 (1) ◽

Author(s):

Iwona Malicka ◽

Dawid Marciniak

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Breast Conserving Surgery ◽

Breast Cancer Treatment ◽

Post Treatment ◽

Control Group ◽

Study Group ◽

Complete Decongestive Therapy ◽

The Mean ◽

Decongestive Therapy

AbstractAim of the study was to assess the effects of Complete Decongestive Therapy (CDT) on the extent of lymphedema of the upper extremity in women post cancer treatment.Study group: 20 women after breast cancer treatment with a mean age of 63.15 years (± 8.15). The group was intentionally divided into 2 groups: patients with lymphedema and patients without lymphedema. The first group (study group, n = 10) consisted of women who received CDT. 70% of them had undergone mastectomy and 30% – breast-conserving surgery. In addition, 60% had received radiotherapy, 70% – chemotherapy and 80% – hormone therapy. The mean post-treatment period was 6.2 ± 3.5 years. Patients in the second group (control group, n = 10) did not receive any anti-edema treatments. 90% of them had undergone mastectomy and 10% – breast-conserving surgery. In addition, 40% of study participants had received adjuvant treatment in the form of radiotherapy, 80% – chemotherapy and 50% – hormone therapy. The mean post-treatment period was 6.3 ± 4.4 years. Method: The extent of lymphedema was measured using a centimeter tape and Limb Volumes Professional 5.0 software.A significant reduction in the extent of lymphedema (p = 0.005) was achieved in the CDT group between baseline and post-treatment assessments. No such reduction, however, was found in the control group (p = 0.33).Complete decongestive therapy is an effective method of treatment of lymphedema in women post breast cancer treatment.

Download Full-text

The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment

Sao Paulo Medical Journal ◽

10.1590/s1516-31802007000100005 ◽

2007 ◽

Vol 125 (1) ◽

pp. 22-28 ◽

Cited By ~ 54

Author(s):

Claudio Battaglini ◽

Martim Bottaro ◽

Carolyn Dennehy ◽

Logan Rae ◽

Edgar Shields ◽

...

Keyword(s):

Breast Cancer ◽

Body Composition ◽

Resistance Training ◽

Cancer Treatment ◽

Cancer Patients ◽

Exercise Intervention ◽

Exercise Group ◽

Moderate Intensity ◽

Control Group ◽

Breast Cancer Patients

CONTEXT AND OBJECTIVE: Changes in metabolism have been reported in the majority of patients undergoing cancer treatment, and these are usually characterized by progressive change in body composition. The effects of aerobic exercise programs to combat the cancer and cancer treatment-related side effects, which include the negative changes in body composition, have been extensively reported in the literature. However, few resistance exercise intervention studies have hypothesized that breast cancer patients might benefit from this type of exercise. The purpose of this study was to determine whether exercise protocols that emphasize resistance training would change body composition and strength in breast cancer patients undergoing treatment. DESIGN AND SETTING: Randomized controlled trial, at the Campus Recreation Center and Rocky Mountain Cancer Rehabilitation Institute of the University of Northern Colorado, and the North Colorado Medical Center. METHODS: Twenty inactive breast cancer patients were randomly assigned to a 21-week exercise group (n = 10) or a control group (n = 10). The exercise group trained at low to moderate intensity for 60 minutes on two days/week. The primary outcome measurements included body composition (skinfold method) and muscle strength (one repetition maximum). RESULTS: Significant differences in lean body mass, body fat and strength (p = 0.004, p = 0.004, p = 0.025, respectively) were observed between the groups at the end of the study. CONCLUSION: The results suggest that exercise emphasizing resistance training promotes positive changes in body composition and strength in breast cancer patients undergoing treatment.

Download Full-text

Data-Driven Treatment Pathways Mining for Early Breast Cancer Using cSPADE Algorithm and System Clustering

10.21203/rs.3.rs-69976/v1 ◽

2020 ◽

Author(s):

Qing Yang ◽

Ting Luo ◽

Wei Zhang ◽

Xiaorong Zhong ◽

Ping He ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Early Breast Cancer ◽

Breast Cancer Treatment ◽

Breast Cancer Patients ◽

Treatment Pathways ◽

Kolmogorov Smirnov ◽

System Clustering ◽

Sequence Rules ◽

Smirnov Test

Abstract Background: Due to the multidimensional, multilayered, and chronological order of the cancer data in this study, it was challenging for us to extract treatment paths. Therefore, it was necessary to design a new data mining scheme to effectively extract the treatment path of breast cancer. To determine whether the cSPADE algorithm and system clustering proposed in this study can effectively identify the treatment pathways for early breast cancer. Methods: We applied data mining technology to the electronic medical records of 6891 early breast cancer patients to mine treatment pathways. We provided a method of extracting data from EMR and performed three-stage mining: determining the treatment stage through the cSPADE algorithm → system clustering for treatment plan extraction → cSPADE mining sequence pattern for treatment. The Kolmogorov-Smirnov test and correlation analysis were used to cross-validate the sequence rules of early breast cancer treatment pathways.Results: We unearthed 55 sequence rules for early breast cancer treatment, 3 preoperative neoadjuvant chemotherapy regimens, 3 postoperative chemotherapy regimens, and 2 chemotherapy regimens for patients without surgery. Through 5-fold cross-validation, Pearson and Spearman correlation tests were performed. At the significance level of P <0.05, all correlation coefficients of support, confidence and lift were greater than 0.89. Using the Kolmogorov-Smirnov test, we found no significant differences between the sequence distributions.Conclusions: The cSPADE algorithm combined with system clustering can achieve hierarchical and vertical mining of breast cancer treatment models. By uncovering the treatment pathways of early breast cancer patients by this method, the real-world breast cancer treatment behavior model can be evaluated, and it can provide a reference for the redesign and optimization of the treatment pathways.

Download Full-text

Evaluation of the eating habits of breast cancer patients

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.36.7.2368 ◽

2020 ◽

Vol 36 (7) ◽

Author(s):

Tuba Kayan Tapan ◽

Zeynep Erdogan Iyigun ◽

Serkan Ilgun ◽

Vahit Ozmen

Keyword(s):

Breast Cancer ◽

Fatty Acids ◽

Cancer Patients ◽

Eating Habits ◽

Saturated Fatty Acids ◽

Water Soluble ◽

Control Group ◽

Study Group ◽

Vitamin B2 ◽

Breast Cancer Patients

Objective: To determine the relationship between the dietary characteristics of breast cancer patients. Methods: Patients with breast cancer whose treatments have finished and are in remission formed the study group and healthy people formed the control group. Demographic, anthropometric characteristics, food consumption frequency form and exercise status were recorded with all groups. Data analysis was done by SPSS 22. Results: In the study group, mean carbohydrate percentage was lower, while fat, fat percentage, monosaccharide, glucose, fructose, omega3(n3), saturated fatty acids(SFA), monounsaturated fatty acids (MUFA), vitamin A, C, E, B6, biotin and copper values were significantly higher (p<0.05). Recurrence was observed in seven patients (7.1%) during the follow-up period, hormone receptor levels (ER) and vitamin B2 intake (accuracy 93.9%) were inversely related to the recurrence of the disease (p=0.02). Conclusions: While the percentage of carbohydrate taken was lower in study group; total fat, n3, SFA, MUFA, monosaccharide, glucose, fructose, water-soluble fiber, B6, biotin and copper values were higher. Further studies are needed for vitamin B2 deficiency in patients with recurrence. doi: https://doi.org/10.12669/pjms.36.7.2368 How to cite this:Tapan TK, Iyigun ZE, Ilgun S, Ozmen V. Evaluation of the eating habits of breast cancer patients. Pak J Med Sci. 2020;36(7):---------. doi: https://doi.org/10.12669/pjms.36.7.2368 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text

Probiotics for the Treatment of Docetaxel-Related Weight Gain of Breast Cancer Patients—A Single-Center, Randomized, Double-Blind, and Placebo-Controlled Trial

Frontiers in Nutrition ◽

10.3389/fnut.2021.762929 ◽

2021 ◽

Vol 8 ◽

Author(s):

Zhang Juan ◽

Zhang Qing ◽

Liang Yongping ◽

Liyuan Qian ◽

Wei Wu ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Weight Gain ◽

Cancer Treatment ◽

Cancer Patients ◽

Body Fat ◽

Breast Cancer Treatment ◽

Body Fat Percentage ◽

Breast Cancer Patients ◽

Fat Percentage

Background: Docetaxel is an important chemotherapy-agent for breast cancer treatment. One of its side-effects is weight gain, which increases the all-cause mortality rate. Considering gut microbiota is one important factor for weight regulation, we hypothesized that probiotics could be potentially used to reduce the docetaxel-related weight gain in breast cancer patients.Methods: From 10/8/2018 to 10/17/2019, 100 breast cancer (Stage I-III) patients underwent four cycles of docetaxel-based chemotherapy were enrolled and randomly assigned to receive probiotics (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) or placebo (supplementary material of the probiotics capsule) treatment for 84 days with three capsules per time, twice/day. The primary outcome: the changes in body weight and body-fat percentage of the patients were measured by a designated physician using a fat analyzer, and the secondary outcomes: the fasting insulin, plasma glucose, and lipids were directly obtained from the Hospital Information System (HIS); The metabolites were measured using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS); The fecal microbiome was analyzed using bacterial 16S ribosomal RNA (rRNA) gene sequence. All indicators were measured 1 day before the first cycle of docetaxel-based chemotherapy and 21 days after the last cycle of docetaxel-based chemotherapy.Results: Compared with the placebo group, the probiotic group showed significantly smaller changes in body weight (Mean [SD] 0.77 [2.58] vs. 2.70 [3.08], P = 0.03), body-fat percentage (Mean [SD] 0.04 [1.14] vs. 3.86 [11.09], P = 0.02), and low density lipoprotein (LDL) (Mean [SD]−0.05[0.68] vs. 0.39 [0.58], P = 0.002). Moreover, five of the 340 detected plasma metabolites showed significant differences between the two groups. The change of biliverdin dihydrochloride (B = −0.724, P = 0.02) was inverse correlated with weight gain. One strain of the phylum and three strains of the genus were detected to be significantly different between the two groups. Also, the changes of Bacteroides (B = −0.917, P < 0.001) and Anaerostipes (B = −0.894, P < 0.001) were inverse correlated with the change of LDL.Conclusions: Probiotics supplement during docetaxel-based chemotherapy for breast cancer treatment may help to reduce the increase in body weight, body-fat percentage, plasma LDL, and minimize the metabolic changes and gut dysbacteriosis.Clinical Trial Registration:http://www.chictr.org.cn/showproj.aspx?proj=24294, ChiCTR-INQ-17014181.

Download Full-text

Factors influencing options in primary breast cancer treatment.

Journal of Clinical Oncology ◽

10.1200/jco.1987.5.1.68 ◽

1987 ◽

Vol 5 (1) ◽

pp. 68-74 ◽

Cited By ~ 42

Author(s):

W H Wolberg ◽

M A Tanner ◽

E P Romsaas ◽

D L Trump ◽

J F Malec

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Cancer Patients ◽

Primary Breast Cancer ◽

Breast Cancer Treatment ◽

Cancer Information ◽

Breast Cancer Patients ◽

Term Survival ◽

Tumor Excision ◽

Factors Influencing

Primary breast cancer treatment is determined by tumor factors and by patient preference. Breast cancer treatments that preserve the cosmetic appearance of the breast are appealing and effective for appropriately selected patients; long-term survival following tumor excision and breast irradiation appears to be comparable to that for mastectomy. Since April 1981, when a protocol was developed and treatment options were offered, factors influencing treatment selection have been analyzed in 206 consecutive primary breast cancer patients. Mastectomy was dictated by tumor-related factors in 96 patients (47%); 110 patients (53%) had the option of mastectomy or conservation--tumor excision plus radiotherapy to the breast. Among these 110 eligible patients, 54 chose conservation (49%) and 56 chose mastectomy (51%). Intraoperative findings for ten patients electing conservation necessitated mastectomy, so conservation was accomplished for 44 (21%) of those treated for breast cancer. Beginning in July 1982, breast cancer patients took a battery of psychosexual assessments before any operation (Profile of Mood States [POMS], Health Locus of Control Scale [HLCS] Locke-Wallace Marital Adjustment Test [MAT], Psychosocial Adjustment to Illness Scale [PAIS], Derogatis Sexual Function Inventory [DSFI], Millon Clinical Multiaxial Inventory [MCMI], and a Breast Cancer Information Test [BCIT]). Comparisons of psychologic and demographic variables were made between patients who chose mastectomy and those who chose conservation. No demographic variable was statistically significantly related to choice, although older women tended to select mastectomy more than younger women. Compared with those who elected conservation, women who elected mastectomy were more tense and anxious (P less than .01), more introverted (P less than .01), felt more depressed and dejected (P less than .05), and reported more sexual problems (P less than .05). Those who elected conservation valued their physical appearance more highly (P less than .01) and were generally more self-interested (P less than .05). Mastectomy was dictated by medical considerations for approximately half of patients with breast cancer. Among candidates for breast conservation, the importance of retaining the breast appeared to be determined to a significant degree by measurable psychological factors.

Download Full-text

Availability, accessibility, and impact of social support on breast cancer treatment among breast cancer patients in Kumasi, Ghana: A qualitative study

PLoS ONE ◽

10.1371/journal.pone.0231691 ◽

2020 ◽

Vol 15 (4) ◽

pp. e0231691 ◽

Cited By ~ 1

Author(s):

Awolu Adam ◽

Felix Koranteng

Keyword(s):

Breast Cancer ◽

Social Support ◽

Qualitative Study ◽

Cancer Treatment ◽

Cancer Patients ◽

Breast Cancer Treatment ◽

Breast Cancer Patients

Download Full-text

Serum metabolism during breast cancer treatment.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e23043 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e23043-e23043

Author(s):

Guro Fanneløb Giskeødegård ◽

Torfinn Støve Madssen ◽

Riyas Vettukattil ◽

Vidar Gordon Flote ◽

Anders Husøy ◽

...

Keyword(s):

Breast Cancer ◽

Weight Gain ◽

Cancer Treatment ◽

Cancer Patients ◽

Breast Cancer Treatment ◽

Post Treatment ◽

Breast Cancer Patients ◽

National Guidelines ◽

Lipoprotein Subfractions ◽

Metabolite Profiles

e23043 Serum metabolism during breast cancer treatment Background: Breast cancer treatment may include surgery, systemic therapy and radiation, often involving side-effects. Many patients experience weight gain during treatment, which is associated with decreased survival rates1. The purpose of this study was to describe serum metabolic alterations in breast cancer patients undergoing treatment, and relate these alterations to weight gain during treatment. Methods: This pilot study includes 60 breast cancer patients, aged 35-75 years, with histologically verified stage I/II disease. All patients underwent tumor surgery, and were treated according to national guidelines. Samples were collected before and 6 months after surgery, and analyzed by MR spectroscopy (MRS) and mass spectrometry (MS). 170 metabolites and 105 lipoprotein subfractions were quantified by combined MRS and MS analyses. Results: Multilevel PLS-DA showed significant alterations in serum metabolite profiles post-treatment, both in patients receiving (n = 35) and not receiving (n = 25) chemotherapy (classification accuracy: 86.7% and 77.0%, resp., p < 0.001). Lipoprotein profiles were also significantly altered in both groups (p < 0.001). Chemotherapy recipients had decreased levels of citrate, ornithine, and methionine after treatment, while non-recipients had increased levels of glutamate, alanine, proline and two biogenic amines, and decreased levels of acylcarnitines. 17/52 patients (32.7%) gained weight (≥ 1.5 kg) during treatment. Weight gain was predicted from pre-treatment samples with accuracy 67.0% (p = 0.020). Weight gain patients had lower levels of three acylcarnitines and 20 phosphocholines, and higher levels of lysine and isoleucine, suggesting aberrant lipid and amino acid metabolism. Weight gain was also reflected in the post-treatment samples (accuracy 66.8%, p = 0.015), with weight gain patients having higher levels of five acylcarnitines, and lower levels of glycine, isoleucine and valine. Conclusions: This study indicates that treatment induces changes in serum metabolite levels. Patients gaining weight had significantly different metabolite profiles than those not gaining weight both before and after treatment. 1. Chan et al, Ann Oncol 25: 1901-14, 2014.

Download Full-text

Predictive Value of Serum Aurora A, Thymidine Kinase 1, and HER3/ErbB3 in Breast Cancer Patients Before Neoadjuvant Treatment

10.21203/rs.3.rs-1233138/v1 ◽

2022 ◽

Author(s):

Pawel Winter ◽

Beata Kotowicz ◽

Malgorzata Fuksiewicz ◽

Maria Kowalska ◽

Agnieszka Jagiello-Gruszfeld ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Neoadjuvant Treatment ◽

Growth Factor Receptor ◽

Breast Cancer Treatment ◽

Control Group ◽

Breast Cancer Patients ◽

Thymidine Kinase 1 ◽

Epidermal Growth

Abstract Further personalization is needed to improve the outcomes of breast cancer treatment. It is necessary to find new inexpensive and easily evaluated predictive markers. In this study, we determined serum level of Aurora A (AURKA), thymidine kinase 1 (TK1) and human epidermal growth factor receptor type 3 (HER3) by enzyme immunoassay ELISA. We collected peripheral blood sera of 119 women with breast cancer before neoadjuvant treatment and the control group of 47 randomly selected healthy women. After treatment we analyzed clinical data: age, initial TNM stage, tumor receptors expression: estrogen (ER), progesterone (PGR), epidermal growth factor receptor type 2 (HER2), Ki67, histological malignancy grade, biological subtype, and response to neoadjuvant treatment in residual cancer burden (RCB) classification. Pathologic complete response (PCR) was achieved in 41 patients (34.45%). In univariate analysis patients with higher AURKA levels were more likely to obtain PCR (p=0.039). In multivariate analysis we used the logit regression model with PCR as the dependent. The effect of AURKA concentration ≥4.75 ng / mL on the chance of achieving PCR was found (OR: 3.5; 95%CI: 1.2-10.1; p = 0.023). Other significant PCR factors included: node status (OR: 0.503; 95% CI: 0.263-0.965; p = 0.039), negative PGR expression (OR: 0.104; 95% CI: 0.038-0.284; p < 0.001), and Ki67 >20% (OR: 5.44; 95% CI: 1.24-23,9; p < 0.025). There was no significance in marker concentrations and clinical features nor between breast cancer patients and control group. The outcomes suggest that serum AURKA level is a potential PCR prediction marker in neoadjuvant breast cancer treatment. Further studies are needed to confirm our observations.

Download Full-text